NextCure Q2 net loss $17.9M; cash $185.5M funds ops into Q1 2024

NextCure, Inc.

2022-Q2 EPS reported -$1.39

Net loss $17.9M in Q2 2022 vs $18.0M in Q2 2021; no revenue reported.
Cash, equivalents, and marketable securities $185.5M at June 30, down from $219.6M at Dec 31.
Cash runway expected to fund operations into the first quarter of 2024.
R&D expenses $12.8M (+$0.9M YoY); G&A expenses $5.3M (-$0.7M YoY).
Upcoming milestones: NC318 Phase 2 update Q4 2022, NC410/NC762 data H2 2022, NC525 IND filing Q4 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.